Serum mannose-binding lectin as a biomarker in neonatal sepsis

Abstract

Objective The aim of thi s study was to evaluate the levels of mannose-binding lectin (MBL) in neonates to determine the relation between MBL deficiency and the development of sepsis. Background The MBL is a member of the collection family that is produced by the liver as an acute-phase protein. MBL activates macrophages, enhances phagocytosis, and contributes toward complement activation. Low serum MBL levels increase the risk of infections, especially if associated with other conditions such as immune deficiencies of various origins. Neonates are considered to be immunocompromised because their adaptive immunity has not yet been developed. Patients and methods This case–control study was carried out on 86 neonates classified into two groups: 45 neonates diagnosed with sepsis and 41 healthy neonates with no clinical signs or laboratory evidence of sepsis who were enrolled as a control group. Assessment of history, clinical examination, and investigations (complete blood count, C-reactive protein, blood culture, MBL levels) were performed for all neonates. Results The mean MBL serum level was found to be lower in the septic group (0.49 ± 0.1) than the control group (1.4 ± 0.3) with high statistical significance. Conclusion Low MBL serum levels are related to the development of sepsis.